Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study
Real-world evidence regarding the effectiveness of prulifloxacin in the treatment of acute exacerbations of chronic bronchitis (AECB) is limited. Therefore, this study aimed to assess the rates and time to symptom improvement and resolution in patients with moderate-to-severe AECB who were given pru...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2021/6620585 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566441823436800 |
|---|---|
| author | Konstantinos Gourgoulianis Alessandro Ruggieri Alessandra del Vecchio Fabrizio Calisti Alessandro Comandini Giovanna Esposito Giorgio Di Loreto Nikolaos Tzanakis |
| author_facet | Konstantinos Gourgoulianis Alessandro Ruggieri Alessandra del Vecchio Fabrizio Calisti Alessandro Comandini Giovanna Esposito Giorgio Di Loreto Nikolaos Tzanakis |
| author_sort | Konstantinos Gourgoulianis |
| collection | DOAJ |
| description | Real-world evidence regarding the effectiveness of prulifloxacin in the treatment of acute exacerbations of chronic bronchitis (AECB) is limited. Therefore, this study aimed to assess the rates and time to symptom improvement and resolution in patients with moderate-to-severe AECB who were given prulifloxacin in the routine care in Greece. This observational, prospective study, conducted in 15 hospital-based clinics across Greece, enrolled outpatients >40 years old, with moderate-to-severe AECB, for whom the physician had decided to initiate treatment with prulifloxacin. Data were collected at prulifloxacin onset (baseline), 7–10 days after baseline, and at least 28 days after therapy completion. Between 23 November 2015 and 27 January 2018, 305 patients (males: 76.4%; mean (standard deviation) (SD) age: 69.7 (9.8) years; Anthonisen type I/II: 94.8%; chronic bronchitis duration >10 years: 24.9%) were consecutively enrolled. At baseline, >80% had increased sputum volume, cough, dyspnoea, and sputum purulence. Prulifloxacin improved symptoms in 99.7% of the patients after a mean (SD) of 5.47 (3.57) days, while symptoms fully recovered after a mean (SD) of 10.22 (5.00) days in 95.4%. The rate of adverse events related to prulifloxacin was 1.3% (serious: 0.7%). In the routine care in Greece, prulifloxacin was highly effective in moderate-to-severe AECB, while displaying a predictable safety profile. |
| format | Article |
| id | doaj-art-cffed6926a0e45dbbf1791b4d2b61263 |
| institution | Kabale University |
| issn | 1198-2241 1916-7245 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-cffed6926a0e45dbbf1791b4d2b612632025-02-03T01:04:08ZengWileyCanadian Respiratory Journal1198-22411916-72452021-01-01202110.1155/2021/66205856620585Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” StudyKonstantinos Gourgoulianis0Alessandro Ruggieri1Alessandra del Vecchio2Fabrizio Calisti3Alessandro Comandini4Giovanna Esposito5Giorgio Di Loreto6Nikolaos Tzanakis7University Respiratory Clinic, University General Hospital of Larissa, Larissa 41110, GreeceΑngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, ItalyΑngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, ItalyΑngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, ItalyΑngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, ItalyΑngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, ItalyΑngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, ItalyUniversity Respiratory Clinic, University General Hospital of Heraklion (PE.PA.GNI), Heraklion 71110, GreeceReal-world evidence regarding the effectiveness of prulifloxacin in the treatment of acute exacerbations of chronic bronchitis (AECB) is limited. Therefore, this study aimed to assess the rates and time to symptom improvement and resolution in patients with moderate-to-severe AECB who were given prulifloxacin in the routine care in Greece. This observational, prospective study, conducted in 15 hospital-based clinics across Greece, enrolled outpatients >40 years old, with moderate-to-severe AECB, for whom the physician had decided to initiate treatment with prulifloxacin. Data were collected at prulifloxacin onset (baseline), 7–10 days after baseline, and at least 28 days after therapy completion. Between 23 November 2015 and 27 January 2018, 305 patients (males: 76.4%; mean (standard deviation) (SD) age: 69.7 (9.8) years; Anthonisen type I/II: 94.8%; chronic bronchitis duration >10 years: 24.9%) were consecutively enrolled. At baseline, >80% had increased sputum volume, cough, dyspnoea, and sputum purulence. Prulifloxacin improved symptoms in 99.7% of the patients after a mean (SD) of 5.47 (3.57) days, while symptoms fully recovered after a mean (SD) of 10.22 (5.00) days in 95.4%. The rate of adverse events related to prulifloxacin was 1.3% (serious: 0.7%). In the routine care in Greece, prulifloxacin was highly effective in moderate-to-severe AECB, while displaying a predictable safety profile.http://dx.doi.org/10.1155/2021/6620585 |
| spellingShingle | Konstantinos Gourgoulianis Alessandro Ruggieri Alessandra del Vecchio Fabrizio Calisti Alessandro Comandini Giovanna Esposito Giorgio Di Loreto Nikolaos Tzanakis Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study Canadian Respiratory Journal |
| title | Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
| title_full | Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
| title_fullStr | Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
| title_full_unstemmed | Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
| title_short | Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
| title_sort | prulifloxacin effectiveness in moderate to severe acute exacerbations of chronic bronchitis α noninterventional multicentre prospective study in real life clinical practice the aiolos study |
| url | http://dx.doi.org/10.1155/2021/6620585 |
| work_keys_str_mv | AT konstantinosgourgoulianis prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT alessandroruggieri prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT alessandradelvecchio prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT fabriziocalisti prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT alessandrocomandini prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT giovannaesposito prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT giorgiodiloreto prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT nikolaostzanakis prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy |